Drug intelligence / Profile preview

DYN201

Development stage: Preclinical
Lead developer: Flamingo Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

DYN201 is a preclinical therapeutic program from Dynacure aimed at treating hereditary spastic paraplegia type 11 (HSP type 11), the most prevalent autosomal recessive HSP caused by mutations in the SPG11 gene, which are associated with thin corpus callosum, cognitive decline, and lower motor neuron degeneration.[1][7] Publicly available summaries list it as an RNA-targeting approach in the antisense/RNA interference space, consistent with Dynacure’s focus on RNA therapeutics for rare neurological diseases.[1][8]

Other names: DYN-201DYN201DYN 201

Beyond the preview

Go deeper on DYN201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DYN201.

Explore the full profile